Literature DB >> 2553528

[Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin].

L Heilmann1, M Kruck, A E Schindler.   

Abstract

The safety and efficacy of low molecular heparin (Sandoz AG, Nürnberg), given 1500 aPTT once daily (and two placebo injections), in preventing postoperative venous thromboembolism, was assessed against sodium heparin at a dose of 5000 IU three times daily, in a unicenter double-blind randomized study. 300 patients, scheduled for major gynecological surgery, were included in this study. Two patients (1.3%) of 150 patients developed deep vein thrombosis in the LMWH-group, the corresponding figure for sodium heparin was 6 patients (4.0%). There was no statistically significant difference between the two groups in respect to the bleeding variables such as postoperative drainage, blood transfusions and haematoma. The antithrombotic effects were assessed with the anti-Xa assay and LMWH-fractions have shown a high antifactor Xa/activated partial thromboplastin time (aPTT) specific activity (2:1) compared to unfractionated heparin (1:1). It is concluded that one single daily injection of LMWH (without dihydergot) provides a convenient safe and effective prophylaxis against thromboembolism in gynecological surgery.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553528     DOI: 10.1055/s-2008-1036089

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  4 in total

1.  Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen.

Authors:  D Voth; M Schwarz; K Hahn; K Dei-Anang; S al Butmeh; H Wolf
Journal:  Neurosurg Rev       Date:  1992       Impact factor: 3.042

2.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

Review 3.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

4.  Cancer-associated thrombosis: prevention and treatment.

Authors:  K M J Brose; A Y Y Lee
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.